La vendita allo scoperto per electroCore dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di electroCore. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

electroCore (NASDAQ:ECOR) Azioni, Report sulle vendite allo scoperto

ELECTROCORE INC

electroCore

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

electroCore Inc

Elcora Advanced Materials Corp

ELCORA ADVANCED MATERIALS by Elcora Advanced Materials Corp.

ECORA RESOURCES U/ADR by ECORA RESOURCES PLC

ECORA RESOURCES PLC by ECORA RESOURCES PLC

Ecora Resources PLC

JP Morgan analyst Bryan Smilek downgrades Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) from Neutral to Underweight.

News

Downgrades

Analyst Ratings

CHGG

JP Morgan Downgrades Chegg to Underweight

Contracts

V2X Awarded $62M Contract To Support COBRA DANE Radar Operational Readiness Through 2027

General

KIDZ

KIDZW

Classover Announces Development Of A Next-Generation Artificial Intelligence Powered Tutoring Platform

JP Morgan analyst Matthew Boss upgrades Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) from Neutral to Overweight and lowers the price target from $19 to $17.

Upgrades

Price Target

LEVI

JP Morgan Upgrades Levi Strauss to Overweight, Lowers Price Target to $17

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $133 price target.

Reiteration

BPMC

Needham Reiterates Buy on Blueprint Medicines, Maintains $133 Price Target

JP Morgan analyst Richard Shane upgrades Essent Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESNT#NYSE">ESNT</a>) from Neutral to Overweight and maintains the price target from $60 to $60.

ESNT

JP Morgan Upgrades Essent Group to Overweight, Maintains Price Target to $60

Management

Harley-Davidson's Board Of Directors Confirm On-Going CEO Search Process

As global markets continue to swing wildly in the aftermath of Trump's tariffs coming into play, an old observation from Berkshire Hathaway&#8217;s former vice-chair, <a href="https://www.benzinga.com/25/04/44659224/billionaire-charlie-munger-said-hed-be-the-richest-man-on-earth-if-he-could-go-back-100-years-and-start-over-i-could-have-done-a-lot-better">Charlie Munger,</a><a href="https://www.benzinga.com/25/04/44659224/billionaire-charlie-munger-said-hed-be-the-richest-man-on-earth-if-he-could-go-back-100-years-and-start-over-i-could-have-done-a-lot-better"> sounds more relevant than ever</a>. 
What Happened: During volatility, Munger once told shareholders: "The market is not going to do exactly what you want when you want it&#8230;&#8221;
&#8220;I wouldn&#8217;t worry too much about what happens over six months or twelve months. I don&#8217;t think you&#8217;re really all that welcome in this room if the short-term orientation is what turns you on."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Charlie Munger: &quot;The market is not going to do exactly what you want when you want it &#8230; I wouldn&#39;t worry too much about what happens over six months or twelve months. I don&#39;t think you&#39;re really all that welcome in this room if the short-term orientation is what turns you on.&quot; <a href="https://t.co/yQLY20cK4P">pic.twitter.com/yQLY20cK4P</a>
&mdash; Kevin Carpenter (@kejca) <a href="https://twitter.com/kejca/status/1908919285847556486?ref_src=twsrc%5Etfw">April 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/04/44680547/dave-ramsey-caller-asks-if-they-should-stop-contributing-during-market-collapse-ten-years-from-now-you-wont-even-remember-this-crap">Dave Ramsey Caller Asks If They Should Stop Contributing During Market Collapse — &#8216;Ten Years From Now You Won&#8217;t Even Remember This Crap&#8217;</a>
Why It Matters: Trump's sweeping tariffs have triggered a <a href="https://www.benzinga.com/general/market-summary/25/04/44679853/wall-street-eyes-recovery-as-sp-500-nasdaq-futures-rise-after-trumps-tariff-driven-selloff-wipes-out-9-trillion-in-six-weeks">market meltdown, wiping out $9 trillion</a> in just six weeks—an impact rivaling the losses seen during the peak of the COVID-19 crash and surpassing the year-long decline following the 2008 Lehman Brothers collapse, according to Bear Traps Report founder Lawrence McDonald.
On Monday, stocks swung as investors responded to contradictory signals. Hopes that tariffs might be halted for a bit pushed the S&amp;P 500 almost 7% from its recent low, only for the market to change course when the Trump administration confirmed the 25% hike on Chinese goods would go ahead. <a href="https://www.benzinga.com/news/global/25/04/44679330/will-trump-impose-higher-tariffs-on-china-crypto-bettors-now-see-an-80-possibility">China threatened retaliation, leading to a fresh wave of uncertainty</a>. By evening, futures for the Dow, S&amp;P 500, and Nasdaq-100 had each climbed by more than 1%.

The recent episode underscores just how reactive markets have become—bouncing on speculation, then falling on confirmation. <a href="https://www.benzinga.com/markets/25/04/44657195/charlie-munger-slams-teaching-stock-trading-to-young-people-its-like-trying-to-induce-young-people-to-start-off-on-heroin">Munger's lesson highlights the danger of chasing headlines</a> and banking on instant gratification from markets that are, by nature, unpredictable.
At a time when even experienced investors are tempted to time the chaos, <a href="https://www.benzinga.com/personal-finance/25/04/44654791/billionaire-charlie-munger-hated-being-told-what-to-do-he-said-getting-rich-meant-you-could-say-to-hell-with-them-and-avoid-needing-anyone">Munger's reminder</a> stands steady: patience beats panic, particularly when the noise is loudest.
Image via Shutterstock
Read Next: <a href="https://www.benzinga.com/25/04/44681272/jim-cramer-questions-market-strength-amid-chinas-retaliatory-tariffs-oversold-panic-or-a-big-trap">Jim Cramer Cautions Against Jumping In As Oversold Market Sparks Futures Rebound Without Clear Catalyst: &#8216;Is It All A Big Trap?&#8217;</a>

Equities

Markets

Charlie Munger Once Said, 'The Market Won't Do Exactly What You Want, When You Want' — As Tariff Jitters And Wild Swings Remind Investors Why Long-Term Thinking Matters

JP Morgan analyst Richard Shane upgrades Guild Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) from Underweight to Neutral and lowers the price target from $12.5 to $12.

GHLD

JP Morgan Upgrades Guild Holdings to Neutral, Lowers Price Target to $12

Health Care

KURA

Kura Oncology Submits New Drug Application (NDA) To The FDA For ziftomenib For The Treatment Of Acute Myeloid Leukemia (AML)

JP Morgan analyst Jimmy Bhullar upgrades RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) from Neutral to Overweight and maintains the price target from $284 to $284.

JP Morgan Upgrades RenaissanceRe Holdings to Overweight, Maintains Price Target to $284

Biotech

Financing

Offerings

IBRX

ImmunityBio Announced Registered Direct Offering Of Approximately $75M In Gross Proceeds With A Single Institutional Investor, If Fully Exercised, The Warrants Could Result In Additional Gross Proceeds Of Up To Approximately $90M

JP Morgan analyst Jimmy Bhullar upgrades Palomar Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLMR#NASDAQ">PLMR</a>) from Neutral to Overweight and raises the price target from $115 to $150.

PLMR

JP Morgan Upgrades Palomar Hldgs to Overweight, Raises Price Target to $150

ZENA

ZenaTech Scales Domestic Drone Production For Commercial And Defense Markets Without Raising Prices

Dividends

SIGA

SIGA Technologies Declared A Special Cash Dividend Of $0.60 Per Share Payable On May 15, 2025, To Shareholders Of Record At The Close Of Business On April 29, 2025

GXAI

Gaxos.ai Launches AI-Enabled Gaxos Health Mobile Application For iOS And Android

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) with a Buy and maintains $23 price target.

LXEO

HC Wainwright & Co. Reiterates Buy on Lexeo Therapeutics, Maintains $23 Price Target

<ul>
<li>Since providing initial guidance, the Company received larger than expected orders during the final week of March, and has also obtained additional visibility into inventory levels on hand at some of our current purchasing customers. Based on this new information, CorMedix is increasing its H1 2025 guidance for Net Sales to existing purchasing customers to a revised range of $62 million to $70 million.</li>
<li>While the Company is currently forecasting net sales from existing purchasing customers in 2Q 2025 to be lower than 1Q 2025, this is due to the timing of shipments to those customers between quarters, and does not suggest an anticipated decrease in patient utilization in the second quarter or the second half of 2025. CorMedix currently forecasts patient utilization with existing purchasing customers to continue to grow throughout 2025 as implementation expands to new patients, and currently anticipates unit shipments in H2 2025 to exceed shipments in H1 2025.</li>
<li>CorMedix expects patient enrollment for our Phase 3 study of DefenCath in patients receiving Total Parenteral Nutrition, or TPN, to begin in late April. The Company believes DefenCath, if approved for this indication, can achieve peak annual sales in this patient population of $150 million to $200 million, with a total addressable market opportunity of $500 million to $750 million.</li>
<li>Cash and short-term investments, excluding restricted cash, at March 31, 2025 amounted to approximately $77.5 million</li>
</ul>

Earnings

Guidance

CRMD

CorMedix Announces Preliminary Revenue Of $39M For 1Q 2025 Vs. Consensus Of $32.20M, And Expects 1Q 2025 Adjusted EBITDA (To Exceed $22.5M Once Final Numbers Are Reported)

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is increasingly behaving like a <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44627407/gold-overtaking-bitcoin-in-inflation-hedge-strategy-jpmorgan-says">high-volatility, liquid version of gold</a>, according to Bernstein analysts.
What Happened: In a note to clients on Tuesday, the analysts wrote that despite falling roughly 26% amid <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44680723/despite-tariff-turmoil-bitcoin-outperforms-magnificent-7-stocks-in-2025-records-smaller-losses-than-nvidia-tesla-apple">ongoing tariff disruptions</a> and geopolitical volatility, Bitcoin has performed better than expected in historical context—especially compared to past market shocks like COVID or rate hike cycles, which triggered 50–70% drawdowns.
The asset&#8217;s resilience during recent global market stress signals a shift toward higher-quality capital and growing institutional adoption, making it a "more liquid and higher-volatility version of gold."
"Bitcoin on a time-scale is probabilistic gold," the note read. "It trades like the most accessible and liquid risk-market when equities are closed, acting as a weekend signal for investor sentiment."
Bernstein&#8217;s report suggests that while Bitcoin has not fully decoupled from traditional equities—and still correlates with risk-on assets—it is increasingly being treated as a long-term store of value. 
The cryptocurrency&#8217;s market capitalization now approaches $2 trillion, still a fraction of gold's $20 trillion market, but it offers greater liquidity and twice the volatility.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44672506/blackrock-ceo-larry-fink-warns-many-already-believe-the-us-is-in-a-recession">BlackRock CEO Larry Fink Warns &#8216;Many Already Believe The US Is In A Recession&#8217;</a>
Why It Matters: Institutional adoption is driving this shift.
Spot Bitcoin ETFs have collectively seen inflows of around $770 million year-to-date despite recent price declines. 
Additionally, large corporate holders such as Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) are <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44671650/strategy-reports-59-billion-in-unrealized-bitcoin-losses-pauses-new-purchases">investing with longer-term horizons</a>, with BTC now comprising significant portions of balance sheets across publicly traded firms.
"The ETF flows are still in positive territory and reflect higher-quality capital," the analysts noted, adding that nearly 10% of Bitcoin's total supply is now held in ETFs and corporate treasuries combined.
While macro headwinds like tariffs on China-based mining hardware could impact Bitcoin mining capacity in the short term, U.S. miners such as Riot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>), CleanSpark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) and Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) are pivoting to AI infrastructure to diversify revenue streams and withstand geopolitical shocks.
Bernstein&#8217;s core thesis remains that Bitcoin's volatility, liquidity, and emerging role in institutional portfolios are cementing its evolution as a digital commodity asset—distinct from gold, but increasingly a peer in investor strategy.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44670129/bitcoin-whipsaws-as-trillions-in-market-value-are-erased-on-fake-tariff-pause-rumor">Bitcoin Whipsaws As Trillions In Market Value Are Erased On Fake Tariff Pause Rumor</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

CLSK

Core Scientific, Inc. - Class A Common Stock

CORZ

MSTR

RIOT

Bitcoin Is A 'More Liquid And Higher Volatility Version Of Gold': Bernstein

GNRC

Generac Strengthens Portfolio With New Generators Designed For The Data Center Market

Press Releases

electroCore to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Legal

electroCore Expands Intellectual Property Portfolio

electroCore's Truvaga™ Now Available on Amazon®

electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal

electroCore to Participate at Upcoming Investor Conferences

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025

electroCore Announces Full Year 2024 Financial Results

electroCore Extends VA Contract for Five Years

electroCore to Participate at the Needham Virtual Healthcare Conference

electroCore Named One of The Americas' Fastest Growing Companies by the Financial Times

ECOR

Apyx Medical

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics

HeartBeam

BioSig Technologies

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

CytoSorbents

Daxor

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

electroCore

Vendite allo scoperto

electroCore (NASDAQ:ECOR) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO